258 related articles for article (PubMed ID: 17269983)
1. Evaluation of oral methotrexate in the treatment of systemic sclerosis.
Krishna Sumanth M; Sharma VK; Khaitan BK; Kapoor A; Tejasvi T
Int J Dermatol; 2007 Feb; 46(2):218-23. PubMed ID: 17269983
[TBL] [Abstract][Full Text] [Related]
2. A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma.
Pope JE; Bellamy N; Seibold JR; Baron M; Ellman M; Carette S; Smith CD; Chalmers IM; Hong P; O'Hanlon D; Kaminska E; Markland J; Sibley J; Catoggio L; Furst DE
Arthritis Rheum; 2001 Jun; 44(6):1351-8. PubMed ID: 11407694
[TBL] [Abstract][Full Text] [Related]
3. Profile of systemic sclerosis in a tertiary care center in North India.
Sharma VK; Trilokraj T; Khaitan BK; Krishna SM
Indian J Dermatol Venereol Leprol; 2006; 72(6):416-20. PubMed ID: 17179615
[TBL] [Abstract][Full Text] [Related]
4. Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
Rook AH; Freundlich B; Jegasothy BV; Perez MI; Barr WG; Jimenez SA; Rietschel RL; Wintroub B; Kahaleh MB; Varga J
Arch Dermatol; 1992 Mar; 128(3):337-46. PubMed ID: 1550365
[TBL] [Abstract][Full Text] [Related]
5. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic strategy combining intravenous cyclophosphamide followed by oral azathioprine to treat worsening interstitial lung disease associated with systemic sclerosis: a retrospective multicenter open-label study.
Bérezné A; Ranque B; Valeyre D; Brauner M; Allanore Y; Launay D; Le Guern V; Kahn JE; Couderc LJ; Constans J; Cohen P; Mahr A; Pagnoux C; Hachulla E; Kahan A; Cabane J; Guillevin L; Mouthon L
J Rheumatol; 2008 Jun; 35(6):1064-72. PubMed ID: 18464307
[TBL] [Abstract][Full Text] [Related]
7. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial.
DeMarco PJ; Weisman MH; Seibold JR; Furst DE; Wong WK; Hurwitz EL; Mayes M; White B; Wigley F; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Clements PJ
Arthritis Rheum; 2002 Nov; 46(11):2983-9. PubMed ID: 12428241
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate as single therapy in Crohn's disease: is its long-term efficacy limited?
Charpignon C; Beau P
Gastroenterol Clin Biol; 2008 Feb; 32(2):153-7. PubMed ID: 18343615
[TBL] [Abstract][Full Text] [Related]
9. Treatment of parthenium dermatitis with methotrexate.
Sharma VK; Bhat R; Sethuraman G; Manchanda Y
Contact Dermatitis; 2007 Aug; 57(2):118-9. PubMed ID: 17627653
[TBL] [Abstract][Full Text] [Related]
10. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial.
Clements PJ; Hurwitz EL; Wong WK; Seibold JR; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen VD; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Furst DE
Arthritis Rheum; 2000 Nov; 43(11):2445-54. PubMed ID: 11083267
[TBL] [Abstract][Full Text] [Related]
11. Long-term treatment of patients affected by systemic sclerosis with cyclosporin A.
Basso M; Filaci G; Cutolo M; Murdaca G; Derchi L; Gianrossi R; Ropolo F; Zentilin P; Sulli A; Puppo F; Indiveri F
Ann Ital Med Int; 2001; 16(4):233-9. PubMed ID: 11799631
[TBL] [Abstract][Full Text] [Related]
12. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
13. Minocycline is not effective in systemic sclerosis: results of an open-label multicenter trial.
Mayes MD; O'Donnell D; Rothfield NF; Csuka ME
Arthritis Rheum; 2004 Feb; 50(2):553-7. PubMed ID: 14872498
[TBL] [Abstract][Full Text] [Related]
14. Period of remission after treatment with UVA-1 in sclerodermic skin diseases.
Kroft EB; van de Kerkhof PC; Gerritsen MJ; de Jong EM
J Eur Acad Dermatol Venereol; 2008 Jul; 22(7):839-44. PubMed ID: 18452527
[TBL] [Abstract][Full Text] [Related]
15. Clinical features of systemic sclerosis.
Al-Adhadh RN; Al-Sayed TA
Saudi Med J; 2001 Apr; 22(4):333-6. PubMed ID: 11331491
[TBL] [Abstract][Full Text] [Related]
16. Low dose methotrexate therapy is effective in late-onset atopic dermatitis and idiopathic eczema.
Zoller L; Ramon M; Bergman R
Isr Med Assoc J; 2008 Jun; 10(6):413-4. PubMed ID: 18669134
[TBL] [Abstract][Full Text] [Related]
17. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
Kawald A; Burmester GR; Huscher D; Sunderkötter C; Riemekasten G
J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
[TBL] [Abstract][Full Text] [Related]
18. A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment.
Hroch M; Chladek J; Simkova M; Vaneckova J; Grim J; Martinkova J
J Eur Acad Dermatol Venereol; 2008 Jan; 22(1):19-24. PubMed ID: 18031504
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate therapy in primary biliary cirrhosis.
Sordá J; Findor J
Acta Gastroenterol Latinoam; 2000; 30(4):221-5. PubMed ID: 11086511
[TBL] [Abstract][Full Text] [Related]
20. Collagenous colitis: oral low-dose methotrexate for patients with difficult symptoms: long-term outcomes.
Riddell J; Hillman L; Chiragakis L; Clarke A
J Gastroenterol Hepatol; 2007 Oct; 22(10):1589-93. PubMed ID: 17845686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
